Sign In
Buy CYAD
$0.470
+0 (+0%)
At Close: Aug 17, 2023
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
04:01pm, Thursday, 07'th Sep 2023
MONT-SAINT-GUIBERT, Belgium, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the B
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
04:00pm, Monday, 04'th Sep 2023
MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces its financial results and recent business
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
04:00pm, Thursday, 24'th Aug 2023
MONT-SAINT-GUIBERT, Belgium, Aug. 24, 2023 (GLOBE NEWSWIRE) -- regulated information / inside information - Celyad Oncology SA (“Celyad” or the “Company”) today announced that it has obtained
Celyad Oncology announces receipt of Nasdaq delisting notice
04:01pm, Monday, 15'th May 2023
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), is a biotechnology company focused on innovative technologies for chimeric
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
01:00am, Friday, 05'th May 2023
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric ant
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
01:00am, Friday, 05'th May 2023
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric ant
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
04:01pm, Monday, 24'th Apr 2023
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric a
Celyad Oncology announces receipt of Nasdaq notice
04:01pm, Tuesday, 04'th Apr 2023
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric a
Celyad Oncology appoints Georges Rawadi as its new CEO
02:00am, Friday, 24'th Mar 2023
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric a
Celyad Oncology reports full year 2022 financial results and recent business highlights
05:01pm, Thursday, 23'rd Mar 2023
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (
Celyad Oncology to announce full year 2022 financial results and host conference call
05:01pm, Friday, 17'th Mar 2023
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innov
Celyad Oncology announces non-cash impairment
02:00am, Wednesday, 15'th Mar 2023
MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innov
Celyad Oncology Announces Non-Cash Impairment
02:00am, Wednesday, 15'th Mar 2023
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), a biotechnology company focused
REPEAT -- Celyad Oncology SA - Letter to Shareholders
01:00am, Wednesday, 01'st Mar 2023
MONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology:
Celyad Oncology SA - Letter to Shareholders
11:16am, Tuesday, 28'th Feb 2023
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology:
